AMES, Iowa, July 08, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will provide a company update at its 2015 Investor Day on Tuesday, July 14 beginning at noon ET at the St. Regis in New York City.
Institutional investors, portfolio managers or equity research analysts interested in attending can contact email@example.com to register or for additional information. Please note that pre-registration is required to attend.
This event will be available to the public via a live webcast at http://media.rampard.com/20150714/. The presentation also will be posted to the Company's website at http://www.newlinkgenetics.com following the event.
About NewLink Genetics Corporation
NewLink Genetics is a biopharmaceutical company focused on discovering, developing and commercializing novel immuno-oncology products to improve treatment options for patients with cancer. NewLink Genetics’ portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink Genetics’ product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. For more information please visit http://www.newlinkgenetics.com.
Cautionary Note Regarding Forward-Looking Statements
Statements made at the upcoming conference may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals and market potential. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink's Annual Report on Form 10-K for the period ended December 31, 2014, and subsequent filings with the Securities and Exchange Commission. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Corporate Contact: Jack Henneman Chief Financial Officer (515) 598-2561 Investor@newlinkgenetics.com Investor Contact: Donna LaVoie or Kristina Coppola LaVoieHealthScience (617) 374-8800, ext. 107/105 firstname.lastname@example.org email@example.com
Source:NewLink Genetics Corporation